Collaborative Antiviral Study Group (CASG)
About
What services does this resource provide?
The Collaborative Antiviral Study Group (CASG) is a multi-center clinical trials group that conducts Phase I – IV pediatric and adult research trials to evaluate novel therapeutic regimens for viral infections in over 100 clinical centers across the country and in select international sites. The emphasis is on infections caused by the herpesvirus family, but other viral illnesses may also be addressed.
The CASG undertakes therapeutic intervention trials of promising therapies for emerging or rare viral diseases or biologic threat agents, studies to identify and quantitate surrogate markers of therapeutic activity for antiviral therapies and to document the development of resistance to these antiviral therapies; studies of rare or emerging viral diseases in special populations ( e.g., immunocompromised, pediatric, elderly, pregnant women); and natural history/pathogenesis studies to support future therapeutic or medical management.
The Central Unit provides medical, laboratory, biostatistical and administrative staff to coordinate research design and regulatory affairs for the clinical centers.
Where are services provided?
The Central Unit (non-Government link) is at the University of Alabama at Birmingham (UAB).
Access
Related Services and Information